BIRAD

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024
Infection, Therapy, Bangladesh Technical Education Board, Parity, AFRRI, USUHS, Cocaine, Medicine, NIAID, NIH, Bar-Ilan University, PLUR, World War II, FDA, PLX, Partnership, 3D, Food, Ageing, GMP, Hope, BIRAD, Plural, Meat, Risk, Outline of health sciences, CDMO, Climate, Climate change, Health, Water, Food and Drug Administration, Coffee, Knowledge, Agriculture, Food security, Negotiation, Good manufacturing practice, Pharmaceutical industry

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

Retrieved on: 
Thursday, February 1, 2024
Cocaine, Gonda, Research, Therapy, CWY, Bar-Ilan University, Addiction, MEAI, Animal, Crave, BIRAD, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the signing of an exclusive long-term license agreement with BIRAD, a research & development company of Bar-Ilan University, to use the joint patent it has with BIRAD for innovative cocaine treatment.

Key Points: 
  • Millions are affected by cocaine addiction worldwide, and the successful application of MEAI [5-Methoxy-2-aminoindane] could revolutionize treatment protocols and offer new hope to those trapped in the cycle of addiction.
  • The trial was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning.
  • Animals previously conditioned with cocaine, received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg.
  • This research also demonstrated MEAI’s unique ability to treat cocaine addiction and its potential to become, if approved by regulatory agencies, the first dedicated cocaine addiction treatment.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023
Bar-Ilan University, Cocaine, Depression, FDA, Crime, PLUR, Pharmaceutics, Plural, PLX, Brain, Drug, Research, Rat, BIRAD, PTSD, Anxiety, U.N, Neurogenesis, Cell, Neuron, PAD, Pharmaceutical industry

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Retrieved on: 
Thursday, December 15, 2022
PEA, Acquisition, Canadian Securities Exchange, MEAI, Depression, Gonda, Clinical trial, Pharmacology, Research, Outline, Mental health, FDA, Hebrew University of Jerusalem, Cocaine, AUD, Science, FSE, Bar-Ilan University, Central nervous system, University, Frankfurt Stock Exchange, CWY, IPO, CSE, Eleazar Sukenik, IP, Obesity, Patent, Development, Patient, Therapy, Pharmaceutical industry, Management, BIRAD

Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.
  • We believe our proprietary CMND-100, 5-methoxy-2-aminoindane (“MEAI”)- based treatment can help provide relief to millions around the world.
  • I joined Clearmind when the company was founded, after a thorough examination of the science and the psychedelic fields.
  • CEO of Clearmind Medicine Inc.
    Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

New Greentech Start-Up, Refhuel, to Develop Reversible Fuel Cell Technology

Retrieved on: 
Monday, February 7, 2022
Alternative Energy, Energy, Hydrogen, Electrochemistry, Tel Aviv Stock Exchange, Hydrogen economy, Department, Multimedia, TASE, Ben-Gurion University of the Negev, Time, Los Alamos National Laboratory, Doctor of Philosophy, Research, Leadership, Student, Technology, Geothermal Development Company, Chemical engineering, University, Joel Rifkin, CEO, Singapore International Energy Week, DCMA, Climate change, BIRAD, Bar-Ilan University, Associate, Invention, Renewable energy, Pharmaceutical industry, Chemistry

A new business, Refhuel, which will focus on reversible fuel cell technology launches today.

Key Points: 
  • A new business, Refhuel, which will focus on reversible fuel cell technology launches today.
  • The pioneering technology to allow reversible fuel cells, which is already in development, has been worked on at Bar-Ilan University in Israel under the leadership of Professor Lior Elbaz.
  • Refhuel is developing a reversible fuel-cell based on a proprietary hydrogen carrier technology that will enable efficient storage and production of energy.
  • We have passed the proof of concept stage and, in time, the technology has the potential to revolutionize energy storage and production.